Clinical Trial Update: BOTOX Effects on Seizure Severity and Susceptibility [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Botox (onabotulinumtoxinA) for effects on seizure severity and susceptibility in drug-resistant focal seizures was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-resistant Epilepsy
• Epilepsy
• Focal Onset Seizures

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Drug-resistant Focal Seizure | Phase 4 | Status: TERMINATED